TLDR:
Key Points:
- Aktiia, a HealthTech company based in Switzerland, raised USD 30M in funding led by Redalpine.
- The funding will be used to accelerate the company’s mission to provide insights into blood pressure management through AI-driven technology.
Article Summary:
Aktiia, a Neuchâtel, Switzerland-based HealthTech company, secured USD 30M in funding with Redalpine leading the round, along with participation from Khosla Ventures, Molten, Translink Capital, Verve, and 415 Capital. The company’s CE-marked device is currently available in seven European markets and approved as a medical device in 44 countries worldwide. Aktiia’s technology offers innovation in blood pressure data collection and machine learning modeling, providing personalized, continuous, and medical-grade blood pressure and heart rate data. The funding will be used to ease the global burden of hypertension by empowering people, researchers, and clinicians with blood pressure data for personalized patient care.
Dr. Mattia Bertschi and Dr. Josep Solà founded Aktiia, and Daniel Graf has joined as the new President and Board Member. The company’s mission is to provide novel understanding and personalized patient care of hypertension through their AI-driven technology. Aktiia’s devices are currently used by over 60,000 customers and healthcare organizations.
